Last reviewed 2026-05-19 · How we verify

LUMENHANCE (MANGANESE CHLORIDE TETRAHYDRATE)

BRACCO · FDA-approved approved ✓ Verified May 2026 Quality 9/100

LUMENHANCE (generic name: MANGANESE CHLORIDE TETRAHYDRATE) is a drug developed by BRACCO. It is currently FDA-approved.

LUMENHANCE is a small molecule modality. It is also known by other names, including Manganese (as chloride) and Manganese Chloride.

At a glance

Generic name	MANGANESE CHLORIDE TETRAHYDRATE
Sponsor	BRACCO
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients With Known or Suspected Focal Liver Lesions and Severe Renal Impairment (Phase 3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LUMENHANCE CI brief — competitive landscape report
LUMENHANCE updates RSS · CI watch RSS
BRACCO portfolio CI

Frequently asked questions about LUMENHANCE

What is LUMENHANCE?

LUMENHANCE (MANGANESE CHLORIDE TETRAHYDRATE) is a pharmaceutical drug developed by BRACCO.

Who makes LUMENHANCE?

LUMENHANCE is developed and marketed by BRACCO (see full BRACCO pipeline at /company/bracco).

What is the generic name of LUMENHANCE?

MANGANESE CHLORIDE TETRAHYDRATE is the generic (nonproprietary) name of LUMENHANCE.

What development phase is LUMENHANCE in?

LUMENHANCE is FDA-approved (marketed).

Manufacturer: BRACCO — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing